JPWO2021207072A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021207072A5 JPWO2021207072A5 JP2022548950A JP2022548950A JPWO2021207072A5 JP WO2021207072 A5 JPWO2021207072 A5 JP WO2021207072A5 JP 2022548950 A JP2022548950 A JP 2022548950A JP 2022548950 A JP2022548950 A JP 2022548950A JP WO2021207072 A5 JPWO2021207072 A5 JP WO2021207072A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- acid sequence
- amino acid
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 10
- 150000007523 nucleic acids Chemical class 0.000 claims 8
- 101000798696 Homo sapiens Transmembrane protease serine 6 Proteins 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 102100032452 Transmembrane protease serine 6 Human genes 0.000 claims 3
- 102000054555 human TMPRSS6 Human genes 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 229940126836 transmembrane protease serine 6 synthesis reducer Drugs 0.000 claims 2
- 241000486679 Antitype Species 0.000 claims 1
- 101000798698 Homo sapiens Transmembrane protease serine 7 Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 108010047374 matriptase 2 Proteins 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063006695P | 2020-04-07 | 2020-04-07 | |
| US63/006,695 | 2020-04-07 | ||
| US202163158265P | 2021-03-08 | 2021-03-08 | |
| US63/158,265 | 2021-03-08 | ||
| PCT/US2021/025775 WO2021207072A1 (en) | 2020-04-07 | 2021-04-05 | Anti-tmprss6 antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023520969A JP2023520969A (ja) | 2023-05-23 |
| JPWO2021207072A5 true JPWO2021207072A5 (enrdf_load_stackoverflow) | 2024-04-26 |
Family
ID=75888147
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548950A Pending JP2023520969A (ja) | 2020-04-07 | 2021-04-05 | 抗ｔｍｐｒｓｓ６抗体及びその用途 |
Country Status (9)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115243762A (zh) | 2020-04-07 | 2022-10-25 | 迈威(美国)生物治疗有限公司 | 抗tmprss6抗体及其用途 |
| US20220411487A1 (en) * | 2021-05-11 | 2022-12-29 | Regeneron Pharmaceuticals, Inc. | Anti-tmprss6 antibodies and uses thereof |
| KR20250128393A (ko) * | 2022-11-25 | 2025-08-27 | 맵웰 테라퓨틱스 인크. | 항-tmprss6 항체 및 그의 용도 |
| WO2024211404A2 (en) * | 2023-04-04 | 2024-10-10 | Disc Medicine, Inc. | Anti-tmprss6 antibodies and uses thereof |
| WO2024211900A1 (en) * | 2023-04-06 | 2024-10-10 | Memorial Sloan-Kettering Cancer Center | Il-10 receptor antibodies and methods of use thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69839147T2 (de) | 1997-06-12 | 2009-02-19 | Novartis International Pharmaceutical Ltd. | Künstliche antikörperpolypeptide |
| WO2005023835A2 (en) * | 2003-09-09 | 2005-03-17 | Irm Llc | Modulators of transmembrane protease serine 6 |
| GB0614201D0 (en) * | 2006-07-18 | 2006-08-23 | Univ Cardiff | Matriptase-2 |
| WO2008097461A2 (en) * | 2007-02-02 | 2008-08-14 | Amgen Inc | Hepcidin and hepcidin antibodies |
| ES2761343T3 (es) | 2011-11-07 | 2020-05-19 | Ionis Pharmaceuticals Inc | Modulación de la expresión de TMPRSS6 |
| AR093620A1 (es) | 2012-12-17 | 2015-06-10 | Lilly Co Eli | Anticuerpos bmp-6 |
| DE112014005975T5 (de) * | 2013-12-17 | 2016-09-15 | Kymab Limited | Menschliche Ziele |
| WO2016071701A1 (en) * | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
| CA3119498A1 (en) * | 2015-07-31 | 2017-02-09 | Medimmune Limited | Methods for treating hepcidin-mediated disorders |
| GB201815629D0 (en) | 2018-09-25 | 2018-11-07 | Kymab Ltd | Antagonists |
| MX2022006495A (es) | 2019-11-29 | 2022-09-07 | Kymab Ltd | Tratamiento para la sobrecarga fisiologica de hierro. |
| CN115243762A (zh) | 2020-04-07 | 2022-10-25 | 迈威(美国)生物治疗有限公司 | 抗tmprss6抗体及其用途 |
| JP2024517686A (ja) | 2021-04-26 | 2024-04-23 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 膜貫通プロテアーゼ、セリン６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物およびその使用方法 |
| EP4329876A1 (en) | 2021-04-27 | 2024-03-06 | Silence Therapeutics GmbH | Sirna targeting tmprss6 for the treatment of myeloproliferative disorders |
-
2021
- 2021-04-05 CN CN202180007339.2A patent/CN115243762A/zh active Pending
- 2021-04-05 CA CA3174339A patent/CA3174339A1/en active Pending
- 2021-04-05 JP JP2022548950A patent/JP2023520969A/ja active Pending
- 2021-04-05 KR KR1020227038805A patent/KR20230007368A/ko active Pending
- 2021-04-05 EP EP21724822.8A patent/EP4126220A1/en active Pending
- 2021-04-05 AU AU2021251087A patent/AU2021251087A1/en active Pending
- 2021-04-05 WO PCT/US2021/025775 patent/WO2021207072A1/en active Application Filing
- 2021-04-05 US US17/916,008 patent/US12215170B2/en active Active
- 2021-04-06 TW TW110112433A patent/TW202204422A/zh unknown
-
2023
- 2023-06-05 US US18/329,172 patent/US11866513B2/en active Active